Peptides: promising, poorly tested and often gray-market
September 29, 2026 · 23 min read
Craig Koniver uses peptides clinically, while Huberman's review stresses thin human evidence, tumor questions and sourcing risks, and his growth hormone episode warns about injections. It shows why physician oversight matters in a fast-growing, loosely regulated field.
The rules, numbers and steps worth keeping in front of you.
- Peptides are potent drugs with many effects, and most human evidence is thin.
- Craig Koniver: years of clinic use and good reports, but mostly observation, not trials.
- Andrew Huberman: BPC-157 has strong animal data and almost no human studies.
- Huberman: BPC-157 promotes blood vessel growth, which could also feed a tumor.
- Growth hormone and its secretagogues can help tumors grow and suppress natural signals.
- Each peptide has its own profile; some raise appetite, prolactin and cortisol.
- Combining BPC-157 with growth hormone peptides: Koniver favors it, Huberman warns against it.
- Avoid products labeled for research only; contamination and anaphylaxis are real risks.
- Use regulated compounding pharmacies or drug companies through a board-certified physician.
- Use the minimum effective dose, take breaks, and never dose daily without end.
- Rule out tumors first, then monitor blood work and sleep.
- Under 30 with no clinical need: Huberman sees no reason to raise growth hormone.
- Try behaviors first: hard exercise, early-night sleep, no food two hours before bed.
- Legal status keeps changing; talk to a qualified physician before starting or stopping anything.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.